Vesper Medical

Executive Summary

Vesper Medical is a medical device company focused on deep venous disease, primarily through its Vesper DUO Venous Stent System designed for chronic venous insufficiency (CVI). The company is conducting the VIVID clinical trial to evaluate the stent system's safety and efficacy. Acquired by Philips, Vesper Medical strengthens Philips' therapeutic devices portfolio in the venous space. The VIVID trial, which enrolls patients with symptomatic iliofemoral venous outflow obstruction, is a pivotal study that could support regulatory submissions and market expansion. With a novel dual-stent design addressing anatomical challenges in the iliac and femoral veins, the Vesper DUO system differentiates from competitors. The acquisition by Philips provides significant resources and commercial infrastructure, potentially accelerating adoption upon approval. However, the company's success hinges on positive VIVID trial outcomes and favorable regulatory decisions.

Upcoming Catalysts (preview)

• Q3 2026VIVID Pivotal Trial Data Readout70% success
• Q4 2026FDA Premarket Approval (PMA) Submission60% success